

Bausch Health Announces 2024 Annual Meeting of Shareholder Results

May 15, 2024

LAVAL, Quebec, May 15, 2024– Bausch Health Companies Inc. (NYSE/TSX: BHC) today announced the results of its 2024 annual meeting of shareholders.

Annual Meeting Results

The 10 directors nominated at the Company’s 2024 annual meeting of shareholders held on May 14, 2024, were elected by a vote of the shareholders. The detailed results of the vote for the election of directors are set out below:

Name	For	Withheld	Broker Non-Votes
Thomas J. Appio	181,373,219	10,918,741	70,931,303
Christian A. Garcia	181,143,285	11,148,675	70,931,303
Brett M. Icahn	170,144,670	22,147,290	70,931,303
Sarah B. Kavanagh	180,316,464	11,975,496	70,931,303
Frank D. Lee	173,147,642	19,144,318	70,931,303
Steven D. Miller	177,700,669	14,591,291	70,931,303
Dr. Richard C. Mulligan	175,256,854	17,035,106	70,931,303
John A. Paulson	179,422,691	12,869,269	70,931,303
Robert N. Power	173,228,670	19,063,290	70,931,303
Amy B. Wechsler, M.D.	181,626,477	10,665,483	70,931,303

At the annual meeting of shareholders, shareholders also approved, in a non-binding advisory vote, the compensation of the Company’s named executive officers, an amendment to the Company’s 2014 Omnibus Incentive Plan to increase the number of common shares authorized for issuance thereunder, and appointed PricewaterhouseCoopers LLP as the Company’s

independent registered public accounting firm until the close of the Company's 2025 annual meeting of shareholders.

For the purposes of Toronto Stock Exchange (TSX) approval with respect to the Plan, the Company relied on the exemption set forth in Section 602.1 of the TSX Company Manual, which provides that the TSX will not apply its standards to certain transactions involving eligible inter-listed issuers on a recognized exchange, such as the NYSE.

The final vote tabulation on all matters voted on at the meeting will be reported to the U.S. Securities and Exchange Commission on a current report on Form 8-K, and such report will be made available on the Company's SEDAR profile and on the Company's website at www.bauschhealth.com

About Bausch Health

Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals and eye health, through our controlling ownership of Bausch + Lomb Corporation. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. For more information, visit

www.bauschhealth.com

and connect with us on

[LinkedIn](#)

Investor Contact:

Garen Sarafian
ir@bauschhealth.com

(877) 281-6642 (toll-free)

Media Contact:

Kevin Wiggins
corporate.communications@bauschhealth.com

(908) 541-3785



Investor Inquiries

ir@bauschhealth.com

877-281-6642

514-856-3855 (Canada)

Media inquiries

Corporate.communications@bauschhealth.com

908-569-3692

[LEGAL NOTICE](#)

[PRIVACY POLICY](#)

[EMAIL ALERTS](#)

[EMAIL PAGE](#)

[RSS FEED](#)

Use of this site signifies your agreement to the Legal Notice and Privacy Policy.
©2026 Bausch Health Companies Inc. All rights reserved. MTB.0230.USA.18 V2.0

CALIFORNIA RESIDENTS: DO NOT SELL MY PERSONAL INFORMATION